{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T08:52:03Z","timestamp":1770454323426,"version":"3.49.0"},"reference-count":44,"publisher":"Becaris Publishing Limited","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold>Psoriatic arthritis is a chronic disease that can result in disability and decreased quality of life.<jats:bold>Materials &amp; methods:<\/jats:bold>A prospective cohort was conducted in Brazil. Disease activity was measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Clinical Disease Activity Index (CDAI), functionality by the Health Assessment Questionnaire Disability Index (HAQ-DI) and the quality of life by the EuroQol 5D (EQ-5D).<jats:bold>Results:<\/jats:bold>In total, 122 patients were included. After 6 months, a median reduction of 2.03 in the BASDAI, 7.80 in the CDAI, 0.63 in the HAQ-DI and increase of 0.12 in the EQ-5D was observed. A good clinical response was observed in 45.5% of the patients by BASDAI and 54.5% by CDAI. Higher education and better quality of life were identified as predictors of effectiveness. The most common side effects were the infections.<jats:bold>Conclusion:<\/jats:bold>Anti-TNF-\u03b1 drugs were effective and safe. The incorporation of them into the Brazilian Public Health System has provided therapeutic alternatives to the treatment of psoriatic arthritis.<\/jats:p>","DOI":"10.2217\/cer-2018-0017","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T11:35:39Z","timestamp":1538480139000},"page":"989-1000","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness and safety of anti-TNF in psoriatic arthritis patients in Brazil: a post-incorporation analysis"],"prefix":"10.57264","volume":"7","author":[{"given":"Michael Ruberson Ribeiro","family":"da Silva","sequence":"first","affiliation":[{"name":"Postgraduate Program in Medicines &amp; Pharmaceutical Assistance, College of Pharmacy, Federal University of Minas Gerais, President Ant\u00f4nio Carlos Avenue, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais 31270-901, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9ssica Barreto Ribeiro","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Postgraduate Program in Medicines &amp; Pharmaceutical Assistance, College of Pharmacy, Federal University of Minas Gerais, President Ant\u00f4nio Carlos Avenue, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais 31270-901, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra Maciel","family":"Almeida","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Federal University of Minas Gerais, President Ant\u00f4nio Carlos Avenue, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais 31270-901, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana Maria","family":"Kakehasi","sequence":"additional","affiliation":[{"name":"Medicine School, Federal University of Minas Gerais, Professor Alfredo Balena Avenue, 190, Belo Horizonte, Minas Gerais 30130-100, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haliton Alves","family":"de Oliveira Junior","sequence":"additional","affiliation":[{"name":"Postgraduate Program in Medicines &amp; Pharmaceutical Assistance, College of Pharmacy, Federal University of Minas Gerais, President Ant\u00f4nio Carlos Avenue, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais 31270-901, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"\u00c1lvares-Teodoro","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Federal University of Minas Gerais, President Ant\u00f4nio Carlos Avenue, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais 31270-901, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco de Assis","family":"Acurcio","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Federal University of Minas Gerais, President Ant\u00f4nio Carlos Avenue, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais 31270-901, Brazil"},{"name":"Medicine School, Federal University of Minas Gerais, Professor Alfredo Balena Avenue, 190, Belo Horizonte, Minas Gerais 30130-100, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"8","key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/17512433.2017.1329009","article-title":"Tumor necrosis factor inhibitors in psoriatic arthritis","volume":"10","author":"Mantravadi S","year":"2017","unstructured":"Mantravadi S , Ogdie A , Kraft WK . Tumor necrosis factor inhibitors in psoriatic arthritis . Expert Rev. Clin. Pharmacol. 10 ( 8 ), 899 \u2013 910 ( 2017 ).","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"4","key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie A","year":"2015","unstructured":"Ogdie A , Weiss P . The epidemiology of psoriatic arthritis . Rheum. Dis. Clin. North Am. 41 ( 4 ), 545 \u2013 568 ( 2015 ).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3899\/jrheum.120258","article-title":"Pharmacoeconomic issues in psoriatic arthritis","volume":"89","author":"Olivieri I","year":"2012","unstructured":"Olivieri I , D'Angelo S , Palazzi C Pharmacoeconomic issues in psoriatic arthritis . J. Rheumatol. Suppl. 89 , 103 \u2013 105 ( 2012 ).","journal-title":"J. Rheumatol. Suppl."},{"key":"e_1_3_5_6_2","article-title":"Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature","author":"Gossec L","year":"2017","unstructured":"Gossec L , McGonagle D , Korotaeva T Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature . J. Rheumatol. pii:jrheum.170449 ( 2017 ) ( Epub ahead of print ).","journal-title":"J. Rheumatol."},{"key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2015-208466","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"75","author":"Ramiro L","year":"2016","unstructured":"Ramiro L , Smolen JS , Landew\u00e9 R Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis . Ann. Rheum. Dis. 75 , 490 \u2013 498 ( 2016 ).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates LC","year":"2016","unstructured":"Coates LC , Kavanaugh A , Mease PJ Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis . Arthritis Rheumatol. 68 , 1060 \u2013 1071 ( 2016 ).","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec L","year":"2016","unstructured":"Gossec L , Smolen JS , Ramiro S European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update . Ann. Rheum. Dis. 75 ( 3 ), 499 \u2013 510 ( 2016 ).","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.semarthrit.2016.09.005","article-title":"Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: a prospective cohort study","volume":"46","author":"Aaltonen K","year":"2017","unstructured":"Aaltonen K , Heinonen A , Joensuu J Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: a prospective cohort study . Semin. Arthritis Rheum. 46 ( 6 ), 732 \u2013 739 ( 2017 ).","journal-title":"Semin. Arthritis Rheum."},{"issue":"2","key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3899\/jrheum.150805","article-title":"Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-\u03b1 drugs","volume":"43","author":"Perrotta FM","year":"2016","unstructured":"Perrotta FM , Marchesoni A , Lubrano E . Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-\u03b1 drugs . J. Rheumatol. 43 ( 2 ), 350 \u2013 355 ( 2016 ).","journal-title":"J. Rheumatol."},{"issue":"2","key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry","volume":"63","author":"Glintborg B","year":"2011","unstructured":"Glintborg B , \u00d8stergaard M , Dreyer L Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry . Arthritis Rheum. 63 ( 2 ), 382 \u2013 390 ( 2011 ).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_5_13_2","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Gabinete do Ministro . Portaria n\u00ba 2981 de 26 de novembro de 2009. Aprova o Componente Especializado da Assist\u00eancia Farmac\u00eautica ( 2009 ). Anexo IV . http:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/gm\/2009\/prt2981_26_11_2009_rep.html ."},{"issue":"8","key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification Criteria for Psoriatic Arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor W","year":"2006","unstructured":"Taylor W , Gladman D , Helliwell P Classification Criteria for Psoriatic Arthritis: development of new criteria from a large international study . Arthritis Rheum. 54 ( 8 ), 2665 \u2013 2673 ( 2006 ).","journal-title":"Arthritis Rheum."},{"issue":"12","key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1136\/ard.2010.129726","article-title":"Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?","volume":"69","author":"Eder L","year":"2010","unstructured":"Eder L , Chandran V , Shen H , Cook RJ , Gladman DD . Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann. Rheum. Dis. 69 ( 12 ), 2160 \u2013 2164 ( 2010 ).","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.vhri.2013.01.009","article-title":"Societal preferences for EQ-5D health states from a Brazilian population survey","volume":"2","author":"Viegas Andrade M","year":"2013","unstructured":"Viegas Andrade M , Noronha K , Kind P Societal preferences for EQ-5D health states from a Brazilian population survey . Value Health Reg. Iss. 2 ( 3 ), 405 \u2013 412 ( 2013 ).","journal-title":"Value Health Reg. Iss."},{"issue":"2","key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"486","DOI":"10.5812\/ijem.3505","article-title":"Normality tests for statistical analysis: a guide for non-statisticians","volume":"10","author":"Ghasemi A","year":"2012","unstructured":"Ghasemi A , Zahediasl S . Normality tests for statistical analysis: a guide for non-statisticians . Int. J. Endocrinol. Metab. 10 ( 2 ), 486 \u2013 489 ( 2012 ).","journal-title":"Int. J. Endocrinol. Metab."},{"issue":"3","key":"e_1_3_5_18_2","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"Van Buuren S","year":"2011","unstructured":"Van Buuren S , Groothuis-Oudshoorn K . Mice: multivariate imputation by chained equations in R . J. Stat. Software 45 ( 3 ), DOI:10.18637\/jss.v045.i03 ( 2011 ) ( Epub ahead of print ).","journal-title":"J. Stat. Software"},{"key":"e_1_3_5_19_2","unstructured":"R Core Team . R: a language and environment for statistical computing. The R Project for Statistical Computing Vienna Austria . www.R-project.org\/ ."},{"issue":"20","key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects . JAMA 310 ( 20 ), 2191 \u2013 2194 ( 2013 ).","journal-title":"JAMA"},{"issue":"1","key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"e000181","DOI":"10.1136\/rmdopen-2015-000181","article-title":"Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry","volume":"1","author":"Mease PJ","year":"2015","unstructured":"Mease PJ , Collier DH , Saunders KC , Li G , Kremer JM , Greenberg JD . Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry . RMD Open 1 ( 1 ), e000181 ( 2015 ).","journal-title":"RMD Open"},{"key":"e_1_3_5_22_2","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Aten\u00e7\u00e3o a Sa\u00fade . Portaria Conjunta n\u00ba 6\/2017 \u2013 Publicada em 19\/07\/2017. Aprova o Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas da Artrite Psor\u00edaca . http:\/\/conitec.gov.br\/images\/Relatorios\/2017\/Relat\u00f3rio_PCDT_Artrite_Psor\u00edaca_Secret\u00e1rio_n\u00ba277.pdf ."},{"issue":"1","key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jbspin.2014.08.001","article-title":"Treatment response, drug survival and safety of anti-tumour necrosis factor \u03b1 therapy in 193 patients with psoriatic arthritis: a twelve-year \u2018real life\u2019 experience","volume":"82","author":"Soubrier AS","year":"2015","unstructured":"Soubrier AS , Bele-Philippe P , Cortet B Treatment response, drug survival and safety of anti-tumour necrosis factor \u03b1 therapy in 193 patients with psoriatic arthritis: a twelve-year \u2018real life\u2019 experience . Joint Bone Spine 82 ( 1 ), 31 \u2013 37 ( 2015 ).","journal-title":"Joint Bone Spine"},{"issue":"1","key":"e_1_3_5_24_2","first-page":"80","article-title":"The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept","volume":"29","author":"Lubrano E","year":"2011","unstructured":"Lubrano E , Spadaro A , Marchesoni A The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept . Clin. Exp. Rheumatol. 29 ( 1 ), 80 \u2013 84 ( 2011 ).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2474-15-26","article-title":"Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis","volume":"15","author":"Cawson MR","year":"2014","unstructured":"Cawson MR , Mitchell SA , Knight C Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis . BMC Musculoskelet. Disord. 15 , 26 ( 2014 ).","journal-title":"BMC Musculoskelet. Disord."},{"issue":"8","key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10067-011-1680-y","article-title":"The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study","volume":"30","author":"Scarpa R","year":"2011","unstructured":"Scarpa R , Atteno M , Lubrano E The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study . Clin. Rheumatol. 30 ( 8 ), 1063 \u2013 1067 ( 2011 ).","journal-title":"Clin. Rheumatol."},{"issue":"7","key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3899\/jrheum.100698","article-title":"Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial","volume":"38","author":"Gladman DD","year":"2011","unstructured":"Gladman DD , Bombardier C , Thorne C Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial . J. Rheumatol. 38 ( 7 ), 1355 \u2013 1362 ( 2011 ).","journal-title":"J. Rheumatol."},{"key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"823854","DOI":"10.1155\/2012\/823854","article-title":"Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study","volume":"2012","author":"Teoli M","year":"2012","unstructured":"Teoli M , Zangrilli A , Chimenti MS Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study . Clin. Dev. Immunol. 2012 , 823854 ( 2012 ).","journal-title":"Clin. Dev. Immunol."},{"issue":"10","key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00296-014-3006-2","article-title":"Treatment of psoriatic arthritis with anti-TNF-\u03b1 agents: a systematic review and meta-analysis of efficacy, effectiveness and safety","volume":"34","author":"Lemos LL","year":"2014","unstructured":"Lemos LL , de Oliveira Costa J , Almeida AM Treatment of psoriatic arthritis with anti-TNF-\u03b1 agents: a systematic review and meta-analysis of efficacy, effectiveness and safety . Rheumatol. Int. 34 ( 10 ), 1345 \u2013 1360 ( 2014 ).","journal-title":"Rheumatol. Int."},{"issue":"4","key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kep423","article-title":"Efficacy and safety of anti-TNF-\u03b1 therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register","volume":"49","author":"Saad AA","year":"2010","unstructured":"Saad AA , Ashcroft DM , Watson KD Efficacy and safety of anti-TNF-\u03b1 therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register . Rheumatology (Oxford) 49 ( 4 ), 697 \u2013 705 ( 2010 ).","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/jcpt.12045","article-title":"Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis","volume":"38","author":"F\u00e9nix-Caballero S","year":"2013","unstructured":"F\u00e9nix-Caballero S , Alegre-del Rey EJ , Casta\u00f1o-Lara R Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis . J. Clin. Pharm. Ther. 38 ( 4 ), 286 \u2013 293 ( 2013 ).","journal-title":"J. Clin. Pharm. Ther."},{"issue":"3","key":"e_1_3_5_32_2","first-page":"227","article-title":"Comiss\u00e3o de Espondiloartrites da Sociedade Brasileira de Reumatologia. Recommendations for the management and treatment of psoriatic arthritis","volume":"53","author":"Carneiro S","year":"2013","unstructured":"Carneiro S , Azevedo VF , Bonfiglioli R Comiss\u00e3o de Espondiloartrites da Sociedade Brasileira de Reumatologia. Recommendations for the management and treatment of psoriatic arthritis . Rev. Bras. Reumatol. 53 ( 3 ), 227 \u2013 241 ( 2013 ).","journal-title":"Rev. Bras. Reumatol."},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2016-0027"},{"issue":"1","key":"e_1_3_5_34_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40744-016-0026-2","article-title":"Real life experience of first course of anti-TNF-\u03b1 treatment in ankylosing spondylitis patients in Brazil","volume":"3","author":"Machado MA","year":"2016","unstructured":"Machado MA , Almeida AM , Kakehasi AM , Acurcio FA . Real life experience of first course of anti-TNF-\u03b1 treatment in ankylosing spondylitis patients in Brazil . Rheumatol. Ther. 3 ( 1 ), 143 \u2013 154 ( 2016 ).","journal-title":"Rheumatol. Ther."},{"issue":"1","key":"e_1_3_5_35_2","doi-asserted-by":"crossref","first-page":"e000415","DOI":"10.1136\/rmdopen-2016-000415","article-title":"Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial","volume":"3","author":"Mease PJ","year":"2017","unstructured":"Mease PJ , Kavanaugh A , Coates LC Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial . RMD Open 3 ( 1 ), e000415 ( 2017 ).","journal-title":"RMD Open"},{"issue":"1","key":"e_1_3_5_36_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen JS","year":"2018","unstructured":"Smolen JS , Sch\u00f6ls M , Braun J Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force . Ann. Rheum. Dis. 77 ( 1 ), 3 \u2013 17 ( 2018 ).","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"e_1_3_5_37_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease PJ","year":"2014","unstructured":"Mease PJ , Armstrong AW . Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis . Drugs 74 ( 4 ), 423 \u2013 441 ( 2014 ).","journal-title":"Drugs"},{"key":"e_1_3_5_38_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/CCID.S124886","article-title":"Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis","volume":"10","author":"Carneiro C","year":"2017","unstructured":"Carneiro C , Chaves M , Verardino G Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis . Clin. Cosmet. Investig. Dermatol. 10 , 155 \u2013 163 ( 2017 ).","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"issue":"2","key":"e_1_3_5_39_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","article-title":"The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis","volume":"44","author":"Matcham F","year":"2014","unstructured":"Matcham F , Scott IC , Rayner L The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis . Semin. Arthritis Rheum. 44 ( 2 ), 123 \u2013 130 ( 2014 ).","journal-title":"Semin. Arthritis Rheum."},{"issue":"2","key":"e_1_3_5_40_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ker216","article-title":"Work disability in psoriatic arthritis: a systematic review","volume":"51","author":"Tillett W","year":"2012","unstructured":"Tillett W , de-Vries C , McHugh NJ . Work disability in psoriatic arthritis: a systematic review . Rheumatology (Oxford) 51 ( 2 ), 275 \u2013 283 ( 2012 ).","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"e_1_3_5_41_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi S","year":"2016","unstructured":"Minozzi S , Bonovas S , Lytras T Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis . Expert Opin. Drug Saf. 15 ( Suppl. 1 ), 11 \u2013 34 ( 2016 ).","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"e_1_3_5_42_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials","volume":"148","author":"Garcia-Doval I","year":"2012","unstructured":"Garcia-Doval I , Carretero G , Vanaclocha F Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials . Arch. Dermatol. 148 ( 4 ), 463 \u2013 470 ( 2012 ).","journal-title":"Arch. Dermatol."},{"issue":"11","key":"e_1_3_5_43_2","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren RB","year":"2015","unstructured":"Warren RB , Smith CH , Yiu ZZN Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) . J. Invest. Dermatol. 135 ( 11 ), 2632 \u2013 2640 ( 2015 ).","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"e_1_3_5_44_2","doi-asserted-by":"crossref","first-page":"e003627","DOI":"10.1136\/bmjopen-2013-003627","article-title":"Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study","volume":"4","author":"Goldfien RD","year":"2014","unstructured":"Goldfien RD , Ng MS , Yip G Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study . BMJ Open 4 ( 1 ), e003627 ( 2014 ).","journal-title":"BMJ Open"},{"issue":"6","key":"e_1_3_5_45_2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/acr.22232","article-title":"Cost-utility analysis of a multidisciplinary strategy to manage osteoarthritis of the knee: economic evaluation of a cluster randomized controlled trial study","volume":"66","author":"Marra CA","year":"2014","unstructured":"Marra CA , Grubisic M , Cibere J Cost-utility analysis of a multidisciplinary strategy to manage osteoarthritis of the knee: economic evaluation of a cluster randomized controlled trial study . Arthritis Care Res. (Hoboken) 66 ( 6 ), 810 \u2013 816 ( 2014 ).","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"3","key":"e_1_3_5_46_2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/acr.23293","article-title":"The cost\u2013effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of the TICOPA trial","volume":"70","author":"O'Dwyer JL","year":"2018","unstructured":"O'Dwyer JL , Meads DM , Hulme CT The cost\u2013effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of the TICOPA trial . Arthritis Care Res. (Hoboken) 70 ( 3 ), 462 \u2013 468 ( 2018 ).","journal-title":"Arthritis Care Res. (Hoboken)"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2018-0017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T23:26:42Z","timestamp":1720654002000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2018-0017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.2217\/cer-2018-0017"],"URL":"https:\/\/doi.org\/10.2217\/cer-2018-0017","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}